Glucose Sensing Demand and Access Expansion Drive Record Patient Additions (DXCM Q1 2026 Earnings Call)

Global Demand and Access Expansion Power Solid Top and Bottom Line Gains

DexCom, Inc. generated worldwide revenue of 1.19 billion dollars for the first quarter, representing a 15 percent reported growth rate compared to the prior year. This robust performance was driven by strong international volume growth and expanded commercial access in the U.S. geographic segment. The company successfully expanded its active user base globally, which set a new patient record during the quarter.

The company converted this top-line expansion into high-quality profitability, achieving a gross profit margin of 63.5 percent. This gross margin represents a substantial expansion from the 57.5 percent gross margin recorded in the first quarter of fiscal year 2025. Consequently, net income reached 216.3 million dollars, demonstrating excellent operating efficiency across manufacturing operations.

Operating Efficiencies and Strong Cost Controls Support Raised Profitability Outlines

Jereme M. Sylvain raised the full-year non-GAAP operating profit margin guidance to a range of 23 percent to 23.5 percent. This increase reflects solid operational discipline, even though full-year revenue guidance was reaffirmed at 5.16 billion to 5.20 billion dollars. Discussing the cash position, Jereme M. Sylvain stated: 'We remain in a great financial position, closing the quarter with approximately $2.4 billion of cash and cash equivalents.'

Reimbursement Wins and Launch of G7 15-day Drive Substantial Geographic Expansion

In the U.S. geographic segment, revenue totaled 832 million dollars, representing an 11 percent increase compared to the prior year. This U.S. performance was bolstered by the commercial launch of the DexCom, Inc. G7 15-day system across all channels. Additionally, the company secured a major reimbursement win with Prime Therapeutics, which will cover the CGM system for all people with diabetes starting this summer.

International geographic segment revenue grew 26 percent to reach 360 million dollars, driven by access expansions in countries like France and Canada. The team is also preparing the international launch of Stello. Management projects that these catalysts will help convert nearly 50 percent of the existing U.S. G Series user base to the G7 15-day product by the end of the year.

Clinical Readouts and Category Penetration Indicate Long-Term Growth Opportunities

During the Q&A session, Jacob Steven Leach addressed a question from David Roman of Goldman Sachs regarding U.S. category penetration, noting that only about 30 percent of covered lives currently use CGM. Responding to Larry Biegelsen of Wells Fargo, management confirmed that the defining randomized control trial for type 2 non-insulin patients will have its first readout at the ADA Scientific Sessions. Regarding the CMS coverage timing, Jacob Steven Leach stated: 'As we have said before, we continue to view this decision as only a matter of time.'